PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

Core Viewpoint - PetVivo Holdings, Inc. has announced a strategic collaboration with Commonwealth to promote and clinically implement its innovative joint health products, SPRYNG and Precise PRP, in elite equine athletes [1][2][4]. Company Overview - PetVivo Holdings, Inc. is a biomedical device company focused on developing and commercializing medical devices and therapeutics for companion animals, holding twelve patents and six proprietary trade secrets [6]. - The company's lead product, SPRYNG, is designed for managing lameness and joint-related issues in animals, while Precise PRP is an off-the-shelf platelet-rich plasma product for veterinary use [6]. Collaboration Details - The partnership with Commonwealth aims to integrate SPRYNG and Precise PRP into care protocols for thoroughbred horses, focusing on joint health, performance longevity, and recovery [2][4]. - Both companies will also explore co-branded content and educational initiatives to raise awareness about joint wellness in the equine health community [3]. Leadership Statements - John Lai, CEO of PetVivo, emphasized the significance of the partnership with Commonwealth in showcasing the benefits of their technology for equine health [4]. - Chase Chamberlin, CEO of Commonwealth, highlighted the potential of SPRYNG and Precise PRP to enhance preventive and rehabilitative care for horses, aligning with new welfare protocols [4]. - Mike Eldred, Board Director at PetVivo, noted that the collaboration represents a significant step towards becoming a market leader in equine joint health and regenerative medicine [4].